Condition: Medicated for patients suffering from Pulmonary/Respiratory Diseases. Ease of Use: ★★★★ Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody which is generally recommended for the patients suffering from extreme asthma, It is prescribed to patients who are 18 years old and over with an eosinophilic phenotype. It is not recommended for other problems which are caused […]
-
Signs That the Future Is a Lot Closer Than You Think Apr 26, 2021
-
5 Benefits of Monoclonal Antibodies Oct 6, 2021
-
How Has Technology Transformed Healthcare? Jun 23, 2021
-
Rethinking Drug Discovery Apr 5, 2023
-
Rethinking Drug Discovery Mar 29, 2023
-
Technology That’s Helping Create Targeted Drugs Sep 12, 2022
-
How To Improve Pharma Care In South-East Asia Mar 22, 2022
-
Is The World Ready For A Mental Health Pandemic? Mar 7, 2022
-
Yaqoob on The Six Great Shifts
Really Informative article from Mr.
-
Yaqoob on The Arab Drug Industry
Arab Drug Industry is dominating but need to concentrate on (...)
-
Yaqoob on Outsourcing preclinical and clinical R&D to China
China is leading the world in R&D as they have low-cost (...)
-
Ameeruddin on Next Generation Pharmacovigilance
I really like the article and the way it was editing... The (...)
-
Ameeruddin on Quality Challenges in Drug Delivery
I really like the article and the way it was edited... The (...)